Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD123 targeted CAR-NK cells · 1 trial · 4 indications
The incidence of adverse events after CD123 CAR-NK cell infusion was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)
Objective response rate at 4W±7D and 3M±7D after CAR-NK infusion (Objective response rate includes CR, CRi)
| Arm | Type | Description |
|---|---|---|
| Acute Myeloid Leukemia | EXPERIMENTAL | Infusion of CD123-targeted CAR-NK cells by dose of 1-10x10\^6 cells/kg |
| Blastic Plasmacytoid Dendritic Cell Neoplasm | EXPERIMENTAL | Infusion of CD123-targeted CAR-NK cells by dose of 1-10x10\^6 cells/kg |
| Name | Type | Description |
|---|---|---|
| CD123 targeted CAR-NK cells | BIOLOGICAL | Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion. |
Inclusion Criteria: 1. Gender is not limited, age 18-75 years old (including the threshold value); 2. The expression of CD123 in tumor cells was detected by flow cytometry. 3. Patients with relapsed/refractory AML or BPDCN diagnosed with CD123 positive: 1) AML: a. Recurrent: After complete response...
CD123 targeted CAR-NK cells is an investigational cell therapy being developed for acute myeloid leukemia (AML). It is also being studied in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed or refractory leukemia. The therapy is currently in Phase 1 clinical development.
CD123 targeted CAR-NK cells targets the CD123 antigen, which is expressed on leukemic cells. The therapy uses natural killer (NK) cells engineered with a chimeric antigen receptor (CAR) to recognize and attack CD123-positive cells. This mechanism is being evaluated in patients with acute myeloid leukemia.
CD123 targeted CAR-NK cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker DTIL. The company is conducting a Phase 1 clinical trial of this investigational therapy for acute myeloid leukemia and related conditions.
CD123 targeted CAR-NK cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients to evaluate the safety and efficacy of the treatment.
CD123 targeted CAR-NK cells is being studied in a Phase 1 clinical trial registered as NCT06006403. This trial is recruiting patients with relapsed or refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm. The study is being conducted in China and aims to enroll 36 participants aged 18 years and older.